Krystal Biotech, Inc. (KRYS) on Decifer

Decifer ranks KRYS number 73 of 277 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 13% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 34% a year and profits grew 127% over the past year.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• We do not have a clean read on how it is run yet.
• Revenue growing about 34% a year and profits up 127% with momentum of 25 out of 35 are impressive, but no worldview role and an unclear read on management cap it.

The current read

The evidence on KRYS lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Krystal Biotech, Inc. operates in biotechnology. That places it inside the Healthcare, Biotech & Devices story.

Read the full KRYS research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.